Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter, Open Label, Randomized Phase III Clinical Trial
Xin Wang,Weiming Han,Wencheng Zhang,Xiaomin Wang,Xiaolin Ge,Yu Lin,Haiwen Zhou,Miaomiao Hu,Wei Wang,Ke Liu,Jianchao Lu,Shuai Qie,Jihong Zhang,Wei Deng,Lan Wang,Chun Han,Minghe Li,Kaixian Zhang,Ling Li,Qifeng Wang,Hongyun Shi,Zhilong Yu,Yidian Zhao,Xinchen Sun,Yonggang Shi,Qingsong Pang,Guowei Cheng,Guangbiao Xi,Zongmei Zhou,Jun Liang,Dongfu Chen,Qinfu Feng,Nan Bi,Tao Zhang,Lei Deng,Wenqing Wang,Wen-Yang Liu,Jianyang Wang,Yirui Zhai,Junjie Wang,Wanqing Chen,Junqiang Chen,Zefen Xiao
DOI: https://doi.org/10.2139/ssrn.4094835
2022-01-01
Abstract:Background: To assess the effectiveness of simultaneous integrated boost radiotherapy (SIB-RT) with concurrent and consolidated oral S-1 chemotherapy for elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).Methods: This multicenter, randomized phase III clinical trial was conducted between March 2017 and April 2020 in patients enrolled in 10 centers in China. Patients were randomized to receive S-1-based definitive SIB-RT followed by consolidation chemotherapy (CRT-CT arm, n = 184) or SIB-RT alone (RT arm, n = 146). The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), and toxicity profile.Findings: After a median follow-up time of 42.9 months in the CRT-CT arm and 44.4 months in the RT arm. The 1-, 3-year OS and PFS was improved in the CRT-CT arm compared with that in the RT arm (72.2% vs. 62.3%, 46.2% vs. 33.9%, , Log-rank P = 0.024 and 60.8% vs. 49.3%, 37.3% vs. 27.9%, Log-Rank P = 0.036, respectively). There was no significant difference in the incidence of toxicities higher than grade 3 in the CRT-CT arm.Interpretation: Oral S-1 chemotherapy administered with SIB-RT should be one of the alternative treatment options for elderly patients with inoperable ESCC as it improves survival outcomes without additional treatment-related toxicities comparing to SIB-RT alone.Trial Registration Details: This study was registered at ClinicalTrials.gov Identifier: NCT02979691.Funding Information: This study was supported by the Beijing Hope Run Special Fund of the Cancer Foundation of China (LC2016L04). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Declaration of Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Ethics Approval Statement: The study protocol was approved by the institutional review boards (reference number, NCC2016 YL-06) and independent ethics committees of the participating centers. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.